Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Kuros BiosciencesCSBTF 76 3-Year FCF Growth Rate is 37.60% as of Jun. 2026, which is 20% above its 10-year median of 31.30. GuruFocus rates CSBTF with a GF Score™ of 76/100 and a GF Value™ of $44.58 (Significantly Undervalued). The stock has 1 warning sign investors should review. Among 587 Medical Devices & Instruments companies, Kuros Biosciences ranks better than 72.06% on this metric.
During the past 12 months, Kuros Biosciences's average Free Cash Flow per Share Growth Rate was -8850.00% per year.
During the past 3 years, the average Free Cash Flow per Share Growth Rate was 37.60% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.
During the past 13 years, the highest 3-Year average Free Cash Flow per Share Growth Rate of Kuros Biosciences was 76.70% per year. The lowest was -20.90% per year. And the median was 31.30% per year.
Kuros Biosciences (OTCPK:CSBTF) 3-Year FCF Growth Rate Explanation
Free Cash Flow per Share is the amount of Free Cash Flow per outstanding share of the company's stock. Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company. It's used in the calculation of Forward Rate of Return (Yacktman) %.
Kuros Biosciences 3-Year FCF Growth Rate Related Terms
CSBTF vs ABT, SYK, MDT: 3-Year FCF Growth Rate Comparison
For the Medical Devices subindustry, Kuros Biosciences's 3-Year FCF Growth Rate, along with its competitors' market caps and 3-Year FCF Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kuros Biosciences 3-Year FCF Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Kuros Biosciences's 3-Year FCF Growth Rate distribution charts can be found below:
* The bar in red indicates where Kuros Biosciences's 3-Year FCF Growth Rate falls into.
Kuros Biosciences 3-Year FCF Growth Rate Calculation
This is the 3-year average growth rate of Free Cash Flow per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.
What does a 3-Year FCF Growth Rate of 37.60% mean?
Kuros Biosciences (CSBTF) has a 3-Year FCF Growth Rate of 37.60% as of Jun. 2026. 3-Year FCF Growth Rate is the 3-year average growth rate of Free Cash Flow per Share. View historical data for Kuros Biosciences and its competitors. This is 20% above median its historical median of 31.30. According to the industry distribution chart, Kuros Biosciences ranks #164 out of 587 companies in the Medical Devices & Instruments industry, placing it in the top 27.9%.
Is Kuros Biosciences' 3-Year FCF Growth Rate too high?
Kuros Biosciences' current 3-Year FCF Growth Rate of 37.60% is 20% above median its 10-year median of 31.30. The Medical Devices & Instruments industry median 3-Year FCF Growth Rate is 18.00. Kuros Biosciences' value of 37.60% is 108.9% above this industry median. Based on the distribution chart, Kuros Biosciences ranks #164 out of 587 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Kuros Biosciences has a GF Score™ of 76/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Kuros Biosciences' 3-Year FCF Growth Rate compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Kuros Biosciences ranks #164 out of 587 companies for 3-Year FCF Growth Rate. This puts Kuros Biosciences in the upper half of its industry. The industry median 3-Year FCF Growth Rate is 18.00. Kuros Biosciences' value of 37.60% is 108.9% above this benchmark. While the company's 10-year median is 31.30 vs. the industry median of 18.00, Kuros Biosciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year FCF Growth Rate for a Medical Devices & Instruments company?
The median 3-Year FCF Growth Rate among Medical Devices & Instruments companies is 18.00, based on 587 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year FCF Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year FCF Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Kuros Biosciences's current 3-Year FCF Growth Rate of 37.60% is 108.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year FCF Growth Rate mean?
A high 3-Year FCF Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year FCF Growth Rate is the 3-year average growth rate of Free Cash Flow per Share. View historical data for Kuros Biosciences and its competitors. For the Medical Devices & Instruments industry, the median 3-Year FCF Growth Rate is 18.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kuros Biosciences's current 3-Year FCF Growth Rate is 37.60%, which is 20% above median its own 10-year median of 31.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kuros Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Kuros Biosciences (CSBTF) is currently considered Significantly Undervalued. The stock's GF Value™ is $44.58, compared to a current price of $24.00 — trading 46.2% below its estimated fair value. The current 3-Year FCF Growth Rate is 37.60%, which is 20% above median its 10-year median of 31.30 and 108.9% above the Medical Devices & Instruments industry median of 18.00. Kuros Biosciences' overall GF Score™ is 76/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year FCF Growth Rate calculated?
3-Year FCF Growth Rate is calculated from a company's financial statements. For Kuros Biosciences (CSBTF), the current 3-Year FCF Growth Rate is 37.60% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Kuros Biosciences (CSBTF) Overvalued in 2026?
Based on GuruFocus' analysis, Kuros Biosciences stock appears to be undervalued.
The current stock price of $24.00 is trading 46.2% below its estimated GF Value™ of $44.58.
GuruFocus considers Kuros Biosciences to be Significantly Undervalued.
Key valuation signals for CSBTF:
3-Year FCF Growth Rate: 37.60% (20% above median its 10-year median of 31.30)
GF Value™: $44.58 vs. price of $24.00 (46.2% below fair value)
Industry Position: 108.9% above the Medical Devices & Instruments median (#164 of 587)
No single metric tells the full story. See the CSBTF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Kuros Biosciences Ltd is a Swiss-based biotech company, focused on developing and commercializing biologic bone graft technologies for musculoskeletal applications, particularly in spine, trauma, extremities, and oncology. It has two reportable segments: i) Medical Devices: This segment includes products such as MagnetOs and Attrax, which are biphasic calcium phosphate (BCP) bone grafts that mimic the porous, trabecular structure of cancellous bone. ii) Legacy Portfolio: This segment includes all non-core products (including Checkmate licensing) that are outside the Group's primary therapeutic focus. The majority of the company's revenue is derived from the Medical Devices segment. Geographically, it generates the maximum revenue from the United States of America.
76GF Score
Get the complete analysis for CSBTF
3-Year FCF Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CSBTF has been successfully added to your 
